Table 1.
Baseline demographics and patients’ characteristics of all patients and of subgroups according to disease outcome (all data collected at baseline)
| |
Outcome |
|||
|---|---|---|---|---|
|
All patients |
Remission |
Progression |
p | |
| N=33 | N=17 (51) * | N=16 (49) | ||
|
Gender (M/F) N(%) |
18/15 (54/46) |
6/11 |
12/4 |
0.016† |
|
Age (yrs) |
49±12 (19–79) |
50±9 |
47±15 |
n.s. |
|
Smoking habits (never/ex/current) N(%) |
5/12/16 (15/36/49) |
5/5/7 |
0/7/9 |
0.055† |
|
BMI (kg/m2) |
26±5 (19–36) |
28±4 |
25±5 |
n.s. |
|
PaO2 (mmHg) |
72±15 (47–117) |
78±13 |
63±12 |
0.002 |
|
A-aDO2 (mmHg) |
37±14 (11–63) |
31±11 |
44±14 |
0.005 |
|
VC (% pred) |
80±16 (44–123) |
88±13 |
69±13 |
0.001 |
|
FEV1 (% pred) |
75±16 (43–104) |
80±15 |
67±13 |
0.014 |
|
TLC (% pred) |
79±17 (42–116) |
85±16 |
70±14 |
0.009 |
|
DLCO (% pred) |
57±19 (21–96) |
66±12 |
42±13 |
0.001 |
|
GM-CSF autoantibody (μg/mL) § |
48±22 |
60±17 |
44±13 |
0.55 |
|
KL-6 (U/mL) |
2049±1893 |
1084±585 |
3334±2267 |
0.001 |
|
LDH (IU/L) § |
283±93 (140–522) |
243±69 |
338±103 |
0.005 |
| CEA (ng/mL) § | 8.5±7 (1–27) | 6±4.5 | 12±5.5 | 0.048 |
Unless otherwise indicated, values are expressed as mean ± SD (range).
n.s.= not significant.
* patients who improved or remained stable and did not receive WLL within 18 months prior to the last evaluation.
§ the cut-off of normality for each biomarker is reported in the methods.
† Fisher's exact test, for all other comparisons in the table Student's t-test was used.